Brainstorm Cell Therapeutics Inc.
BCLI
$1.23
$0.010.82%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 46.70% | -120.88% | 52.32% | 32.77% | -11.16% |
| Total Depreciation and Amortization | -19.70% | -9.23% | -4.48% | -4.48% | -5.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -98.91% | 94.87% | -80.36% | 4,150.00% | 1,680.11% |
| Change in Net Operating Assets | 140.12% | 58.07% | 123.96% | -89.62% | -5,723.38% |
| Cash from Operations | 68.10% | 48.53% | 75.17% | 23.16% | 29.32% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -79.38% |
| Cash from Investing | -93.88% | -- | -- | -- | -81.12% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -68.44% | -- | -17.53% | -21.39% | 1,308.40% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -68.44% | -- | -17.53% | -21.39% | 1,308.40% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -91.63% | -588.02% | 282.17% | -141.95% | 107.80% |